Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for LNA043 for the treatment for osteoarthritis of the knee. Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs.1 LNA043 is being developed as a potential first in class disease modifying treatment for osteoarthritis (OA).
OA is a chronic degenerative disease characterized by a progressive loss of cartilage, leading to pain, loss of joint function and disability. It affects …